Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon Closes $72M in Debt and Equity Funding

NEW YORK – Metabolon announced on Wednesday that it had closed on $72 million in combined debt and equity financing.

In a statement, company President and CEO Rohan Hastie said that it planned to use the funding to grow its client base and further its R&D programs using machine learning for biomarker discovery and precision medicine.

The round included new investor Perceptive Advisors as well as existing investors including EW Healthcare Partners.

Morrisville, North Carolina-based Metabolon also announced that it had appointed Robert Cascella, chief business leader, precision diagnostics and executive vice president at Phillips, to its board of directors.

Last month, Metabolon said it had entered into a multiyear drug development alliance with Germany's Merck KGaA.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.